Protalix BioTherapeutics (PLX) Sees Large Volume Increase

Protalix BioTherapeutics (NYSEAMERICAN:PLX) saw unusually-high trading volume on Friday . Approximately 833,000 shares traded hands during trading, an increase of 13% from the previous session’s volume of 738,542 shares.The stock last traded at $0.45 and had previously closed at $0.43.

PLX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Protalix BioTherapeutics in a report on Thursday, February 1st. Zacks Investment Research cut Protalix BioTherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 10th.

Protalix BioTherapeutics (NYSEAMERICAN:PLX) last issued its earnings results on Wednesday, May 9th. The company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.03. The firm had revenue of $4.55 million for the quarter, compared to the consensus estimate of $4.40 million. During the same period last year, the firm earned ($0.48) earnings per share.



An institutional investor recently raised its position in Protalix BioTherapeutics stock. Opaleye Management Inc. increased its holdings in shares of Protalix BioTherapeutics (NYSEAMERICAN:PLX) by 78.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,260,000 shares of the company’s stock after buying an additional 1,435,000 shares during the quarter. Opaleye Management Inc. owned 2.24% of Protalix BioTherapeutics worth $1,760,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply